Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scient...
Saved in:
Main Authors: | Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/2e783d06a91c488f9fb5a86eeb213adf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
by: Nash AI, et al.
Published: (2019) -
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
by: Savitz AJ, et al.
Published: (2017) -
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019) -
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018) -
Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
by: El Khoury AC, et al.
Published: (2021)